School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

ARS Pharmaceuticals, Inc. SPRY

Healthcare · Biotechnology

$4.23last close 2026-10-09 · market cap $415.69M · delayed data

Trailing returns

1M-19.12%
3M-46.32%
6M-48.85%
1Y-63.47%
5Y-56.12%

Basis: Adjusted daily closes.

What it does

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc.

Open SPRY in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies